Avanos (AVNS) Q2 2025: RFA Segment Grows 14%, Powering Portfolio Focus Post-HA Divestiture
Avanos sharpened its portfolio focus with the hyaluronic acid (HA) divestiture and delivered robust growth in its Radio Frequency Ablation (RFA) business, which expanded 14% year over year, reinforcing its leadership in targeted pain management solutions. Strategic execution in both specialty nutrition and pain management segments offset tariff headwinds and margin pressures, enabling the company to reaffirm full-year guidance despite the loss of HA revenue. Investors should watch for further supply chain realignment and commercial model optimization as Avanos accelerates its three-year transformation and leverages new leadership alignment.
Summary
- Portfolio Realignment Accelerates: Divestiture of the HA business sharpens focus on higher-growth, higher-margin segments.
- RFA Segment Outpaces Market: RFA capital and consumables growth, supported by a dedicated sales push, drives pain management momentum.
- Transformation Initiatives Gain Traction: Commercial and operational optimization efforts underpin confidence in guidance despite tariff volatility.
Performance Analysis
Avanos delivered organic sales growth of 2% in Q2 2025, with both specialty nutrition systems (SNS) and pain management and recovery (PM&R) segments showing resilience against a backdrop of tariff-driven cost inflation and portfolio pruning. The SNS portfolio, which is now the company’s largest and most profitable segment, grew 5% organically, maintaining leadership in internal feeding solutions. Growth was broad-based, with long-term and neonatal product lines outperforming, though distributor order timing in the UK modestly tempered sequential momentum.
The PM&R segment normalized for portfolio exits grew 3.4%, fueled by near 14% year-over-year expansion in the RFA business. This was driven by increased generator sales and higher-margin probe pull-through, with the three-tiered RFA offering gaining traction among physicians and ambulatory surgery centers (ASCs). Operating profit in both core segments was pressured by tariffs, particularly as China-origin goods incurred up to a 145% rate before recent relief. Despite these headwinds, Avanos reaffirmed 2025 revenue and EPS guidance, signaling confidence in ongoing cost containment and commercial execution.
- RFA Pull-Through Drives Margin Mix: Generator sales are catalyzing higher probe volumes, supporting sustainable PM&R growth.
- HA Divestiture Removes Low-Margin Drag: HA exit has minimal impact on bottom line, as price pressure had already constrained profitability.
- Tariff Headwinds Remain Acute: Over $8 million in Q2 tariffs will be expensed in Q3, underscoring ongoing supply chain and cost mitigation urgency.
Free cash flow was negative in the quarter due to tax and capex timing, but management expects approximately $40 million for the year as tariff and supply chain actions take effect. The balance sheet remains flexible with leverage well below 1x, providing capacity for targeted M&A aligned with the SNS strategy.
Executive Commentary
"Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance of our life-sustaining specialty nutrition system segment, along with continued progress in our opioid-sparing pain management and recovery segment. The demand for our product remains robust and I'm pleased with the foundation laid out for our three-year transformation efforts."
Dave Pasitti, Chief Executive Officer
"Our specialty nutrition systems portfolio continues to deliver above market results, growing 5% organically versus prior year, reaffirming our number one position in long-term, short-term, and neonatal internal feeding. Demand for our long-term internal feeding products remains strong and our underlying growth continues to beat market levels."
Jason Pickett, Interim Chief Financial Officer
Strategic Positioning
1. Portfolio Focus and Divestiture Discipline
The sale of the HA business marks a decisive shift toward higher-growth, higher-margin segments, with management emphasizing that the divested business had become margin-dilutive due to persistent pricing pressure. This move simplifies the portfolio, freeing resources to invest in SNS and PM&R, which now comprise the entirety of Avanos' growth narrative.
2. RFA Leadership and Sales Model Evolution
RFA is increasingly the commercial centerpiece of the PM&R segment, with a dedicated sales structure and three-tiered offering that positions Avanos as the go-to RF ablation partner for pain specialists. The company’s focus on generator capital sales is driving recurring probe revenue, a classic razor-and-blade model, and deepening customer loyalty in both domestic and international markets.
3. Specialty Nutrition Systems Expansion
SNS continues to outpace the broader market, leveraging new product launches like CoreGrip and expanded standards of care such as CoreTrack. Neonatal solutions, particularly Neomed, are entering late-stage adoption in North America, but global expansion and innovation are expected to sustain mid-single digit organic growth through 2025.
4. Cost Structure and Tariff Mitigation
Tariff volatility remains a material challenge, with $15 million in incremental costs forecast for the year. Avanos is responding with a multilayered mitigation strategy: pricing actions, cost containment, supply chain investments, and an accelerated exit from China-sourced Neomed products by late 2026. The company is also lobbying for regulatory relief and leveraging temporary tariff exemptions where possible.
5. Leadership Realignment and Transformation Execution
New CFO Scott Gallivan’s appointment signals a continued focus on M&A discipline and transformation, while CEO Pasitti’s addition to the board reinforces alignment between management and governance. The transformation program remains in early innings, with further commercial, operational, and cost optimization initiatives slated for the coming quarters.
Key Considerations
Avanos’ Q2 results reflect a company in active transformation, balancing external cost shocks with internal execution and strategic portfolio pruning. The next phases will test the durability of recent gains and the effectiveness of supply chain and commercial realignment.
Key Considerations:
- Tariff Exposure Remains a Wildcard: Full-year cost impact is still uncertain, with Q2 tariffs higher than planned due to timing of China-origin shipments.
- RFA Growth Sustainability: Continued outperformance depends on maintaining sales momentum and recurring consumable adoption as competitive intensity rises.
- HA Divestiture Clears Path for Margin Expansion: Removal of low-margin, price-pressured HA business should support EPS and EBITDA stability despite revenue loss.
- Supply Chain Investments Underpin Future Cost Structure: Accelerated exit from China sourcing and targeted capex are critical to margin resilience in 2026 and beyond.
Risks
Tariff volatility and supply chain transitions pose ongoing risks to margin and cash flow, with over $8 million in Q2 tariffs to be expensed in Q3 and full mitigation not expected until 2026. Competitive threats in both pain management and specialty nutrition, as well as the pace of commercial model optimization, could pressure growth if execution falters. Regulatory shifts, particularly around reimbursement in surgical pain, add further uncertainty to the outlook.
Forward Outlook
For Q3 2025, Avanos guided to:
- Continued mid-single digit organic growth in SNS
- PM&R segment driven by RFA momentum and ongoing cost actions
For full-year 2025, management reaffirmed guidance:
- Revenue of $665 million to $685 million
- Adjusted EPS of $0.75 to $0.95
Management highlighted several factors that will influence H2 performance:
- Tariff cost absorption and mitigation actions
- Commercial execution in core segments and further supply chain investments
Takeaways
Avanos is executing a multi-year transformation, with the HA divestiture and RFA expansion providing early proof points. Cost pressures remain, but disciplined portfolio management and commercial realignment are stabilizing performance.
- RFA and SNS are now the undisputed growth engines, with margin upside as cost actions take hold and low-return assets are shed.
- Portfolio discipline and leadership changes signal a more focused, agile organization, but execution on supply chain and tariff mitigation will determine medium-term margin trajectory.
- Investors should monitor progress on China supply exit, recurring RFA probe adoption, and the pace of commercial optimization for signs of sustained improvement.
Conclusion
Avanos’ Q2 marks an inflection point, with strategic divestiture and segment-led growth offsetting external cost shocks. The company’s success will hinge on its ability to execute supply chain transitions and sustain commercial momentum in its core platforms.
Industry Read-Through
Medical device peers facing tariff exposure and global supply chain complexity should note Avanos’ proactive mitigation strategies and willingness to divest margin-dilutive assets. The razor-and-blade model in pain management, anchored by capital equipment pull-through, remains a viable growth lever for focused players. Portfolio simplification and targeted innovation in specialty care segments are likely to drive above-market growth for those able to navigate cost headwinds and regulatory shifts. The sector should expect continued M&A activity as companies optimize for scale, profitability, and resilience against macro shocks.